---
schema_version: "secwatch.filing_event.v1"
accession: "0001759138-26-000038"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2026-08-13T11:32:31+00:00"
generated_at: "2026-08-13T11:35:08.948009+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Q2 2026: R&D $44.4M, cash $225.1M; rese-cel milestones on track

## Summary
- R&D expenses $44.4M vs $37.6M in Q2 2025; G&A $7.6M vs $8.3M.
- Cash and investments $225.1M at June 30, 2026, up from $133.6M at Dec 31, 2025; funds ops into mid-2027.
- Registrational RESET-Myositis data on track for mid-2027; BLA submission planned 2H27 with juvenile data for Priority Review Voucher.
- SSc-associated ILD registrational cohort (~25 patients) to initiate 4Q26; PC-free approach incorporated in RESET-MG.
- ElevateBio selected as second CDMO alongside Lonza; 10-year supply agreement with Cellares announced April 2026.

## SEC filing metadata
- accession: 0001759138-26-000038
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2026-08-13T11:32:31+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/0001759138-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/caba-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759138-26-000038
- JSON: https://secwatch.observer/filing/0001759138-26-000038.json
- Plain text: https://secwatch.observer/filing/0001759138-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.